Rapport Therapeutics (RAPP) Invested Capital (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Invested Capital data on record, last reported at $471.5 million in Q1 2026.
- On a quarterly basis, Invested Capital rose 64.96% to $471.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $471.5 million, a 64.96% increase, with the full-year FY2025 number at $484.7 million, up 58.68% from a year prior.
- Invested Capital reached $471.5 million in Q1 2026 per RAPP's latest filing, down from $484.7 million in the prior quarter.
- Over the last five years, Invested Capital for RAPP hit a ceiling of $511.6 million in Q3 2025 and a floor of -$39.6 million in Q1 2024.
- A 4-year average of $241.2 million and a median of $295.6 million in 2024 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: skyrocketed 3671.36% in 2024, then fell 21.78% in 2025.
- Tracing RAPP's Invested Capital over 4 years: stood at -$25.6 million in 2023, then surged by 1291.49% to $305.4 million in 2024, then surged by 58.68% to $484.7 million in 2025, then dropped by 2.71% to $471.5 million in 2026.
- Business Quant data shows Invested Capital for RAPP at $471.5 million in Q1 2026, $484.7 million in Q4 2025, and $511.6 million in Q3 2025.